anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention provides a polymer composition comprising at least one thermal gelling polymer and at least one anionic polymer for cell delivery applications. These injectable polymer compositions are shear-thinning, thixotropic and resorbable. More specifically there is described a hyaluronan (HA) and methylcellulose (MC) based thermogelling cell delivery system (HAMC) that promotes cell survival both in vitro and in vivo. Importantly, HAMC (relative to media alone) enhances survival of transplanted stem/progenitor cells in the injured CNS. HAMC provides a minimally-invasive cell delivery strategy where the microenvironment can be further defined and the differentiation and regenerative capacity further explored. This hydrogel system has applications for minimally-invasive cell delivery to other tissues/organs in the body as well.
FIELD: cosmetology, in particular, agents for skin care after shaving. SUBSTANCE: agent contains new additive from synergistically-acting biologically-active components in the form of complex from water-alcohol-glycerine extract of yarrow grass in addition to usual cosmetic additives such as glycerine, ethyl alcohol, flavor, water and water-alcohol-glycerine extract of yarrow grass. The new additive consists of common nettle, calendula, willow bark with complete or incomplete complex, from one component or more, of burnet roots, European birdcherry fruits, poplar young branches, oak bark and leaves, centaurea flowers, willowweed grass, motherwort grass, and sainfoin grass. For increasing synergistic effect, and using as natural flavor introduced in agent formula are biologically active and fragrant substances in the form of water-alcohol-glycerine extracts of wormwood, and complete or incomplete complex, from one component and more, of thyme, sweetclover, origanum, iris roots, melissa and black currant verdant sprouts. EFFECT: higher antiinflammatory, antiallergenic, hemostatic properties. 1 tbl
<P>PROBLEM TO BE SOLVED: To provide a mud pack coating all or a part of the body such as the face, the hand or the head and washed off after the passage of a suitable time and utilizing characteristics of useful clay buried in the northern area of Okinawa Main Island, Japan, and to provide a method for producing the same.  <P>SOLUTION: The mud pack consists essentially of the clay comprising fine particles having ≤100 μm diameter, containing about ≥60% of alumina silicate and having ≥800°C heat resistance. The mud pack contains an extract from Alpinia speciosa K. Schum., an extract from Aloe arborescens Mill. var. natalensis Berg., an extract from Vitex rotundifolia L. fil. and an extract from a leaf of Hibiscus rosa-sinensis and deep seawater. Fig. 1 is a drawing explaining an apparatus for producing the mud pack in the order of steps.  <P>COPYRIGHT: (C)2004,JPO
INTRODUCTION: Dolutegravir (DTG) is widely used for antiretroviral therapy (ART). We compared weight and blood pressure trends and examined the association between high blood pressure and weight gain among people living with HIV (PLHIV) switching to or starting DTG-based, efavirenz (EFV)-based and ritonavir-boosted atazanavir (ATV/r)-based ART in Zimbabwe.
METHODS: PLHIV aged 18 years or older who started or switched to DTG, EFV or ATV/r-based ART between January 2004 and June 2022 at Newlands Clinic in Harare, Zimbabwe, were eligible. Weight was measured at all visits (Seca floor scales); blood pressure only at clinician-led visits (Omron M2 sphygmomanometer). We used Bayesian additive models to estimate trends in weight gain and the proportion with high blood pressure (systolic >140 mmHg or diastolic >90 mmHg) in the first 2 years after starting or switching the regimen. Finally, we examined whether trends in the proportion with high blood pressure were related to weight change.
RESULTS: We analysed 99,969 weight and 35,449 blood pressure records from 9487 adults (DTG: 4593; EFV: 3599; ATV/r: 1295). At 24 months after starting or switching to DTG, estimated median weight gains were 4.54 kg (90% credibility interval 3.88-5.28 kg) in women and 3.71 kg (3.07-4.45 kg) in men, around twice that observed for ATV/r and over four-times the gain observed for EFV. Prevalence of high blood pressure among PLHIV receiving DTG-based ART increased from around 5% at baseline to over 20% at 24 months, with no change in PLHIV receiving EFV- or ATV/r-based ART. High blood pressure in PLHIV switching to DTG was associated with weight gain, with stronger increases in the proportion with high blood pressure for larger weight gains.
CONCLUSIONS: Among PLHIV starting ART or switching to a new regimen, DTG-based ART was associated with larger weight gains and a substantial increase in the prevalence of high blood pressure. Routine weight and blood pressure measurement and interventions to lower blood pressure could benefit PLHIV on DTG-based ART. Further studies are needed to elucidate the mechanisms and reversibility of these changes after discontinuation of DTG.
OBJECTIVES: To describe delirium incidence before and during the COVID-19 pandemic and examine factors associated with delirium incidence in the long-term care setting.
METHODS: We conducted a retrospective cohort study of Ontario long-term care residents without severe cognitive impairment or baseline delirium with an assessment between February 1, 2019, and March 31, 2021. Data were collected from the interRAI Minimum Data Set (MDS) 2.0. The outcome of interest was delirium development. Selected independent variables were entered into univariate longitudinal generalized estimating equations, followed by multivariate analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) are reported.
RESULTS: A total of 63,913 residents were included within the comparison sample from February 2019 to February 2020. The pandemic sample consisted of 54,867 residents from March 2020 to March 2021. Incidence of delirium in the comparison sample was 3.4% (2158 residents) compared to 3.2% (1746 residents) in the pandemic sample (P = 0.06). Residents who were older, cognitively impaired, and increasingly frail had greater odds of developing delirium. Increased odds were associated with a diagnosis of bipolar disorder (OR 1.27, 95% CI 1.07-1.51) and anxiolytic use (OR 1.12, 95% CI 1.01-1.25). Residents who were newly admitted (OR 0.65, 95% CI 0.60-0.71) and those dependent for activities of daily living (OR 0.46, 95% CI 0.33-0.64) had lower odds of delirium development.
CONCLUSIONS AND IMPLICATIONS: The incidence of delirium did not differ between the year prior to and the first year of the COVID-19 pandemic, indicating that preventative interventions employed by long-term care homes may have been effective. Long-term care residents who are older, frail, cognitively impaired, or had unstable health would benefit from targeted interventions to prevent delirium. Newly admitted residents or those dependent in activities of daily living had lower odds of developing delirium, which could indicate under detection in these groups.
Human Experience: Since the introduction of Paroxetine Tablets in the United States, 342 spontaneous cases of deliberate or accidental overdosage during paroxetine treatment have been reported worldwide (circa 1999). These include overdoses with paroxetine alone and in combination with other substances. Of these, 48 cases were fatal and of the fatalities, 17 appeared to involve paroxetine alone. Eight fatal cases that documented the amount of paroxetine ingested were generally confounded by the ingestion of other drugs or alcohol or the presence of significant comorbid conditions. Of 145 non-fatal cases with known outcome, most recovered without sequelae. The largest known ingestion involved 2,000 mg of paroxetine (33 times the maximum recommended daily dose) in a patient who recovered. 

Commonly reported adverse events associated with paroxetine overdosage include somnolence, coma, nausea, tremor, tachycardia, confusion, vomiting, and dizziness. Other notable signs and symptoms observed with overdoses involving paroxetine (alone or with other substances) include mydriasis, convulsions (including status epilepticus), ventricular dysrhythmias (including torsade de pointes), hypertension, aggressive reactions, syncope, hypotension, stupor, bradycardia, dystonia, rhabdomyolysis, symptoms of hepatic dysfunction (including hepatic failure, hepatic necrosis, jaundice, hepatitis, and hepatic steatosis), serotonin syndrome, manic reactions, myoclonus, acute renal failure, and urinary retention.

  1. Overdosage Management: No specific antidotes for paroxetine are known. Treatment should consist of those general measures employed in the management of overdosage with any drugs effective in the treatment of major depressive disorder. 



Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, or exchange transfusion are unlikely to be of benefit.

A specific caution involves patients who are taking or have recently taken paroxetine who might ingest excessive quantities of a tricyclic antidepressant. In such a case, accumulation of the parent tricyclic and/or an active metabolite may increase the possibility of clinically significant sequelae and extend the time needed for close medical observation (see PRECAUTIONS: Drugs Metabolized by Cytochrome CYP2D6). 

In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians’ Desk Reference  (PDR).
Myopia and its treatment modalities are one of the widely studied areas in vision research. So far all the treatment options have been optical i.e., patients with myopia are either corrected with spectacles, contact lenses or refractive surgery to provide clear vision. NeuroVision's NVC vision correction technology will be a novel method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain). It uses a non-invasive, patient-specific treatment that purports to improve neuronal efficiency and induce improvement in the overall ability to see due to a reduction in noise and increase in signal strength. As visual perception quality depends both on the input received through the eye and the processing in the visual cortex, NeuroVision's technology is hypothesized to compensate for blurred (myopic) inputs, by enhancing neural processing.

We will conduct a clinical evaluation of the effectiveness of this system. The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity, ability to see letters of varying size, and CSF, ability to see black and white lines of varying contrast) will be tested in order to continuously monitor a subject's progress. At the end of a session, the data will be sent to the NeuroVision Web Server. Proprietary algorithmic software will analyze the patient's performance and progress and will generate the parameters for the next treatment session. The purpose of the study is to assess the effect on corrected or uncorrected visual performance following treatment.
For the purposes of dose escalation decisions, a standard 3+3 dose escalation design will be used.The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg. If the MTD is exceeded at cohort 1, de-escalation to cohort 0 (20 mg) will occur. If the MTD is not exceeded in cohort 1, dose escalation will continue based on a standard 3+3 design at the dose levels.
A flexible prognostics and health management (PHM) device is disclosed. Sensor data is generated that quantifies real-time conditions of components in a machine based on sensor signals generated by sensors. A PHM system loads a PHM module that implements externally invokable functions. The PHM system receives an analytics script. The analytics script comprises interpretable commands and predictive learning model parameter values associated with a predictive learning model. Some of the interpretable commands are configured to invoke some of the externally invokable functions with at least some of the predictive learning model parameter values. The PHM module invokes a command interpreter module to interpret an interpretable command and the predictive learning model parameter values and generate first executable bytecodes. The first executable bytecodes execute to generate a notification identifying a predicted future condition of a first component for presentation on a display device.
The automatic classification system and method for hospital garbage based on random forest extracts color features, shape features, texture features and smell features from garbage image data through a color channel statistical method, an edge detection algorithm, a gray level co-occurrence matrix method and a gas chromatography-mass spectrometry combination method. The data set is divided into a training set and a testing set by a k-fold cross validation method. First, a random forest classifier is generated by specifying a number of hyper-parameters such as tree, tree depth, minimum sample size, etc. Then, a random forest model is constructed on the training set, and related classification accuracy is calculated to adjust model parameters. Next, the hospital waste classification model is evaluated on the test set. Finally, the newly generated garbage is classified in real time by a sensor or a camera arranged near a garbage delivery opening of the hospital, and a proper and effective treatment mode is adopted. The random forest garbage classification model not only improves the classification accuracy, but also avoids the condition of overfitting when the sample size is small.
INTRODUCTION: Vancouver B2 periprosthetic hip fractures involve stem stability and they have been classically treated with revision surgery. Crucial factors such as age, clinical comorbidities and functional status are often neglected. The current study aims to compare clinical outcomes between patients treated with open reduction and internal fixation (ORIF) or femoral stem exchange.
METHODS: This is a retrospective study that includes all Vancouver B2 periprosthetic hip fractures in a tertiary referral hospital from 2016 to 2020. Patients were divided into two groups: Group 1. Patients treated with an ORIF and Group 2. Patients treated with stem replacement. The outcomes that were compared between groups included demographic data, functional capacity, complications and mortality.
RESULTS: 29 periprosthetic Vancouver B2 fractures were finally analyzed. 11 (37.9%) were treated with ORIF (Group 1) and 18 (62.1%) by stem replacement (Group 2). Surgery time (143 vs. 160 min), hemoglobin drop (1.8 vs. 2.5 g/dL) and hospital stance (25.5 vs. 29.6 days) were shorter in Group 1. According to complications, 18.2% of patients in the ORIF group had orthopedic complications compared with 44.4% in the revision group. In the revision group, 3 cases needed a two-stage revision and one of these revisions ended up with a resection arthroplasty (Girdlestone). The first-year mortality rate was 27% in Group 1 and 11% in Group 2.
DISCUSSION: ORIF treatment seems to be a less aggressive and complex procedure which can lead to a faster general recovery. Revision surgery can imply a higher risk of orthopedic complications which can be severe and may require further aggressive solutions. The ORIF group mortality was similar to the proximal femur fracture rate (20-30%). In conclusion, ORIF treatment seems to be a good option especially in fragile patients with low functional demand when anatomical reduction is possible.
Compression stockings group consisted of 29 patients with CVD. Patients were recommended medium pressure (23-32 mmHg) compression stockings by the physician. Knee high or thigh high compression stockings were given according to the level of symptoms and signs. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
We describe a bis-benzylidine piperidone, RA190, which covalently binds to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma lines, even those resistant to bortezomib, were sensitive to RA190 via ER stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After p.o. or i.p. dosing of mice, RA190 distributed to plasma and major organs excepting brain, and potently inhibited proteasome function in skin and muscle. RA190 administration i.p. profoundly reduced growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retarded HPV+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses, suggesting its therapeutic potential. The bis-benzylidine piperidone RA190 is a new orally-available proteasome inhibitor. Multiple myeloma, cervical and ovarian cancers are particularly sensitive to RA190.
In this narrative review, we assess the pathophysiology of severe adverse events that presented after vaccination with DNA and mRNA vaccines against COVID-19. The focus is on the perspective of an undersulfated and degraded glycocalyx, considering its impact on immunomodulation, inflammatory responses, coagulation and oxidative stress. The paper explores various factors that lead to glutathione and inorganic sulfate depletion and their subsequent effect on glycocalyx sulfation and other metabolites, including hormones. Components of COVID-19 vaccines, such as DNA and mRNA material, spike protein antigen and lipid nanoparticles, are involved in possible cytotoxic effects. The common thread connecting these adverse events is endotheliopathy or glycocalyx degradation, caused by depleted glutathione and inorganic sulfate levels, shear stress from circulating nanoparticles, aggregation and formation of protein coronas; leading to imbalanced immune responses and chronic release of pro-inflammatory cytokines, ultimately resulting in oxidative stress and systemic inflammatory response syndrome. By understanding the underlying pathophysiology of severe adverse events, better treatment options can be explored.
Individuals randomized to the intervention arm will receive care from a team that consists of a care manager(CM) who is either a nurse practitioner (NP) or physician assistant (PA), supervised by the site PI, and a community health worker (CHW). The CM will follow care protocols developed by the research team. The CHW will serve as a liaison between the patient and the health care system, and mobilize resources and system support to reduce social isolation and improve stroke risk factor control self-management, through a series of workshops and home visits. Intervention participants will receive home blood pressure monitors. Subjects in either arm are eligible to receive their usual source of care. Five hundred participants who have had a stroke or TIA will be enrolled, randomized to the intervention or to usual care in a 1:1 ratio, and followed for 12 months. The impact of the intervention on systolic blood pressure is the primary study outcome; secondary outcomes are other stroke risk factors. Enrollment will occur at four sites in Los Angeles County, and the study sample is projected to include over 90% socioeconomically disadvantaged individuals from minority groups.
The invention discloses a preparation method and a quality control method for schefflera kwangsiensis general flavone extract. The preparation technology for the extract comprises the steps as follows: soaking a schefflera kwangsiensis medicinal material for 0.5 h by adding 8 to 10 times of ethanol by weight, wherein the volume concentration of the ethanol is from 60% to 80%; refluxing and extracting for 2 to 3 times with each time of 1 to 3 h; filtering and mixing filtrate; and decompressing and concentrating the filtrate at the temperature of 75 to 85 DEG.C to the temperature of 60 DEG.C, so as to obtain the extract with relative density of 1.10 to 1.30. The product quality control method mainly adopts a high performance liquid chromatography to detect the content of rutin. The preparation technology provided by the invention has the advantages of stable process parameter, process condition and process technology, high rutin extracting yield and strong industrial applicability. The quality control method provided by the invention has the advantages of high degree of separation, good linear relation, convenience, rapidness, accuracy and stability. Therefore, the quality control method meets the requirements of industrial production, and effectively controls the quality of the schefflera kwangsiensis general flavone extract and a preparation thereof.
A metal- or mineral element-containing composition which comprises: (i) one or more compounds of the following elements: zinc, magnesium, copper, selenium, iron, nickel, titanium, vanadium or aluminium being water soluble and able to form corresponding ions of the aforesaid element when dissolved in water, (ii) one or more ammonium metal ion binding, complexing or sequestering agents, (iii) one or more acids, and (iv) water, is disclosed. The composition has a pH of less than 3 and an electrolytic potential in excess of 200 millivlots. The composition may also comprise one or more additives selected from the group consisting of: vitamin B1, vitamin B3, vitamin B5, vitamin B6, vitamin C, malic acid, a natural diuretic, melatonin and valerian. A method of making the described composition is also disclosed. The composition may be form part of an antimicrobial, antiviral, antiretrovirus or antifungal formulation. The composition may be useful for: -the treatment of foodstuffs as a disinfectant or bactericide -the preservation of plants, flowers, trees or shrubs -the treatment of metal for coating, sealing, plating or otherwise forming an anti-corrosive layer upon a metallic substrate -use in treating or preventing a pathogenic disease or disorder. A mineral dietary supplement containing the described composition is also disclosed. (62) Divided out of 517330